Oligolactic Acid Prodrug-Based Nanomedicines for Cancer Therapy

The objective of this project is to devise a novel prodrug strategy for polymeric nanoparticles, seeking a scale-up process for high prodrug loading of a repertoire of poorly water-soluble anticancer drugs, delayed-release, and enhanced delivery into solid tumors.

We hypothesize that delayed release of oligo(lactic acid)_n-paclitaxel (PTX) prodrug from poly(ethylene glycol)-block-poly(lactic acid) nanoparticles increases safety and potency of PTX, owing to prolonged tumor exposure, which increases drug action at G2/M phase of the cell cycle.

To enhance antitumor activity against triple-negative breast cancer, we devise co-loaded PTX and signal transduction inhibitor oligo(lactic acid)_n-prodrug nanomedicines to prolong, elevate and overlap tumor exposure, aiming for safer and more effective anticancer drug combinations.